Antibody-mediated oral delivery of therapeutic DNA for type 2 diabetes mellitus

다국어 초록 (Multilingual Abstract)

Background: Diabetes mellitus (DM) is a chronic progressive metabolic disease that involves uncontrolled elevation of blood glucose levels. Among various therapeutic approaches, GLP-1 prevents type 2 diabetes mellitus (T2DM) patients from experiencing hyperglycemic episodes. However, the short half-life (< 5 min) and rapid clearance of GLP-1 often limits its therapeutic use. Here, we developed an oral GLP-1 gene delivery system to achieve an extended antidiabetic effect. Methods: Human IgG1 (hIgG1)-Fc-Arg/pDNA complexes were prepared by an electrostatic complexation of the expression plasmid with various ratios of the positively modified Fc fragments of an antibody (hIgG1-Fc-Arg) having a targeting ability to FcRn receptor. The shape and size of the complexes were examined by atomic force and field emission electron microscope. The stability of the complexes was tested in simulated gastrointestinal pH and physiological serum condition. Cellular uptake, transport, and toxicity of the complexes were tested in the Caco-2 cells. Biodistribution and antidiabetic effect of the complexes were observed in either Balb/c mice or Lepdb/db mice. Results: A 50/1 ratio of the hIgG1-Fc-Arg/pDNA produced a complex structure having approximately 40 ~ 60 nm size and also demonstrated protection of pDNA in the complex from the physiological pH and serum conditions. Cellular uptake and transport of the complex were demonstrated in Caco-2 cells having FcRn receptor expression and forming the monolayer-polarized structure. The cellular toxicity of both delivery vehicle and the complex revealed their minimal toxicity comparable with nontoxicity of a commercial transfection reagent. Biodistribution of the complex showed the detectable distribution of the complex in the most parts of gastrointestinal tract due to ubiquitous expression of the FcRn receptors. An in vivo type 2 diabetes treatment study of oral administration of hIgG1-Fc-9Arg/pGLP-1 complexes showed absorption and expression in GI tract of either Balb/c mice or Lepdb/db mice. Conclusion: In this study, we developed an oral GLP-1 gene delivery system on the platform of cationic hIgG1-Fc-9Arg. Prolonged t1/2, less immunoactivity, and better bioactivities of hIgG-Fc-9Arg/pGLP-1 complexes appeared to be a promising approach to achieve potent treatment of type 2 diabetes treatment.

참고문헌 (Reference)

1 Sand KM, "Unraveling the interaction between FcRn and albumin: opportunities for Design of Albumin-Based Therapeutics" 5 : 682-, 2014

2 Furgeson DY, "Tumor efficacy and biodistribution of linear polyethylenimine-cholesterol/DNA complexes" 9 : 837-845, 2004

3 Li Z, "Transfer of IgG in the female genital tract by MHC class I-related neonatal fc receptor (FcRn) confers protective immunity to vaginal infection" 108 : 4388-4393, 2011

4 Bakker JM, "Therapeutic antibody gene transfer: an active approach to passive immunity" 10 : 411-416, 2004

5 Holst JJ, "The physiology of glucagon-like peptide 1" 87 : 1409-1439, 2007

6 Moon MJ, "Structural and molecular conservation of glucagon-like Peptide-1 and its receptor confers selective ligand-receptor interaction" 3 : 141-, 2012

7 Wong SL, "Recurrent hypoglycemia from insulin autoimmune syndrome" 29 : 250-254, 2014

8 Morille M, "Progress in developing cationic vectors for non-viral systemic gene therapy against cancer" 29 : 3477-3496, 2008

9 Kircheis R, "Polycation-based DNA complexes for tumor-targeted gene delivery in vivo" 1 : 111-120, 1999

10 Alhakamy NA, "Polyarginine molecular weight determines transfection efficiency of calcium condensed complexes" 10 : 1940-1948, 2013

11 Unverdorben F, "Pharmacokinetic properties of IgG and various fc fusion proteins in mice" 8 : 120-128, 2016

12 Martz L, "Oral nanoparticles" 6 : 1-, 2013

13 Loretz B, "Oral gene delivery: strategies to improve stability of pDNA towards intestinal digestion" 14 : 311-319, 2006

14 Khatun Z, "Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy" 170 : 74-82, 2013

15 Araujo F, "Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control?" 6 : 1486-1497, 2012

16 Wang Q, "Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist" 5 : e12734-, 2010

17 Motta SBP, "Nanoscale structure of protamine/DNA complexes for gene delivery" 102 : 053703-, 2013

18 Liu JW, "Molecular mechanism of immune response induced by foreign plasmid DNA after oral administration in mice" 13 : 3847-3854, 2007

19 Wang B, "Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes" 10 : 131-145, 2014

20 Gaddy DF, "In vivo expression of HGF/NK1 and GLP-1 from dsAAV vectors enhances pancreatic ss-cell proliferation and improves pathology in the db/db mouse model of diabetes" 59 : 3108-3116, 2010

21 Choi S, "Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes" 12 : 885-891, 2005

22 Eissele R, "Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man" 22 : 283-291, 1992

23 "Global report on diabetes" World Health Organization 2016

24 Petersen N, "Generation of L cells in mouse and human small intestine organoids" 63 : 410-420, 2014

25 Naldini L, "Gene therapy returns to Centre stage" 526 : 351-360, 2015

26 Yechoor V, "Gene therapy progress and prospects: gene therapy for diabetes mellitus" 12 : 101-107, 2005

27 Oh S, "GLP-1 gene delivery for the treatment of type 2 diabetes" 7 : 478-483, 2003

28 Roopenian DC, "FcRn: the neonatal fc receptor comes of age" 7 : 715-725, 2007

29 Jorgensen ML, "Expression of single-chain variable fragments fused with the fc-region of rabbit IgG in Leishmania tarentolae" 13 : 9-, 2014

30 Yang Y, "Expression and characterization of a potent long-acting GLP-1 receptor agonist, GLP-1-IgG2sigma-fc" 11 : e0156449-, 2016

31 Petkova SB, "Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease" 18 : 1759-1769, 2006

32 Vaccaro C, "Engineering the fc region of immunoglobulin G to modulate in vivo antibody levels" 23 : 1283-1288, 2005

33 Haley J, "Effect of clustered peptide binding on DNA condensation" 6 : 249-255, 2010

34 American Diabetes A, "Diagnosis and classification of diabetes mellitus" 27 (27): S5-S10, 2004

35 Hubatsch I, "Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers" 2 : 2111-2119, 2007

36 Alberti KG, "Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation" 15 : 539-553, 1998

37 Kumar SR, "Clinical development of gene therapy: results and lessons from recent successes" 3 : 16034-, 2016

38 Neuber T, "Characterization and screening of IgG binding to the neonatal fc receptor" 6 : 928-942, 2014

39 Dickinson BL, "Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line" 104 : 903-911, 1999

40 Kauffman AL, "Alternative functional in vitro models of human intestinal epithelia" 4 : 79-, 2013

41 Ewe A, "A novel tyrosine-modified low molecular weight polyethylenimine (P10Y) for efficient siRNA delivery in vitro and in vivo" 230 : 13-25, 2016

42 Dan M, "A novel pancreatropic coxsackievirus vector expressing glucagon-like peptide 1 reduces hyperglycemia in streptozotocin-treated mice" 85 : 12759-12768, 2011

43 Souders CA, "A novel in vitro assay to predict neonatal fc receptor-mediated human IgG half-life" 7 : 912-921, 2015

44 Yi SW, "A cationic lipid emulsion/DNA complex as a physically stable and serumresistant gene delivery system" 17 : 314-320, 2000